Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 134 entries
Sorted by: Best Match Show Resources per page
Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer.

Hospital pharmacy

Solimando DA, Waddell JA.
PMID: 24623866
Hosp Pharm. 2014 Feb;49(2):127-33. doi: 10.1310/hpj4902-127.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Solimando DA, Waddell JA. Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. Hosp Pharm. 2014;49(2):127-33doi: 10.1310/hpj4902-127.
Solimando, D. A., & Waddell, J. A. (2014). Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. Hospital pharmacy, 49(2), 127-33. https://doi.org/10.1310/hpj4902-127
Solimando, Dominic A, and Waddell, J Aubrey. "Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer." Hospital pharmacy vol. 49,2 (2014): 127-33. doi: https://doi.org/10.1310/hpj4902-127
Solimando DA, Waddell JA. Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. Hosp Pharm. 2014 Feb;49(2):127-33. doi: 10.1310/hpj4902-127. PMID: 24623866; PMCID: PMC3940678.
Copy Download .nbib Format: NLM
Nivolumab and Olaparib.

Hospital pharmacy

Solimando DA, Waddell JA.
PMID: 26405320
Hosp Pharm. 2015 May;50(5):356-66. doi: 10.1310/hpj5005-356.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Solimando DA, Waddell JA. Nivolumab and Olaparib. Hosp Pharm. 2015;50(5):356-66doi: 10.1310/hpj5005-356.
Solimando, D. A., & Waddell, J. A. (2015). Nivolumab and Olaparib. Hospital pharmacy, 50(5), 356-66. https://doi.org/10.1310/hpj5005-356
Solimando, Dominic A, and Waddell, J Aubrey. "Nivolumab and Olaparib." Hospital pharmacy vol. 50,5 (2015): 356-66. doi: https://doi.org/10.1310/hpj5005-356
Solimando DA, Waddell JA. Nivolumab and Olaparib. Hosp Pharm. 2015 May;50(5):356-66. doi: 10.1310/hpj5005-356. PMID: 26405320; PMCID: PMC4567200.
Copy Download .nbib Format: NLM
Drug monographs: belinostat and idelalisib.

Hospital pharmacy

Piper WL, Waddell JA, Solimando DA.
PMID: 25673888
Hosp Pharm. 2014 Dec;49(11):1009-13. doi: 10.1310/hjp4911-1009.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Piper WL, Waddell JA, Solimando DA. Drug monographs: belinostat and idelalisib. Hosp Pharm. 2014;49(11):1009-13doi: 10.1310/hjp4911-1009.
Piper, W. L., Waddell, J. A., & Solimando, D. A. (2014). Drug monographs: belinostat and idelalisib. Hospital pharmacy, 49(11), 1009-13. https://doi.org/10.1310/hjp4911-1009
Piper, Whitney L, et al. "Drug monographs: belinostat and idelalisib." Hospital pharmacy vol. 49,11 (2014): 1009-13. doi: https://doi.org/10.1310/hjp4911-1009
Piper WL, Waddell JA, Solimando DA. Drug monographs: belinostat and idelalisib. Hosp Pharm. 2014 Dec;49(11):1009-13. doi: 10.1310/hjp4911-1009. PMID: 25673888; PMCID: PMC4319799.
Copy Download .nbib Format: NLM
Drug Monographs: Ixazomib and Necitumumab.

Hospital pharmacy

Lawson FE, Waddell JA, Solimando DA.
PMID: 27303088
Hosp Pharm. 2016 May;51(5):362-6. doi: 10.1310/hpj5105-362.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Lawson FE, Waddell JA, Solimando DA. Drug Monographs: Ixazomib and Necitumumab. Hosp Pharm. 2016;51(5):362-6doi: 10.1310/hpj5105-362.
Lawson, F. E., Waddell, J. A., & Solimando, D. A. (2016). Drug Monographs: Ixazomib and Necitumumab. Hospital pharmacy, 51(5), 362-6. https://doi.org/10.1310/hpj5105-362
Lawson, Fern E, et al. "Drug Monographs: Ixazomib and Necitumumab." Hospital pharmacy vol. 51,5 (2016): 362-6. doi: https://doi.org/10.1310/hpj5105-362
Lawson FE, Waddell JA, Solimando DA. Drug Monographs: Ixazomib and Necitumumab. Hosp Pharm. 2016 May;51(5):362-6. doi: 10.1310/hpj5105-362. PMID: 27303088; PMCID: PMC4896343.
Copy Download .nbib Format: NLM
Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme.

Hospital pharmacy

Rutledge MR, Waddell JA, Solimando DA.
PMID: 26823616
Hosp Pharm. 2015 Sep;50(8):672-7. doi: 10.1310/hpj5008-672. Epub 2015 Sep 16.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Rutledge MR, Waddell JA, Solimando DA. Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme. Hosp Pharm. 2015;50(8):672-7doi: 10.1310/hpj5008-672.
Rutledge, M. R., Waddell, J. A., & Solimando, D. A. (2015). Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme. Hospital pharmacy, 50(8), 672-7. https://doi.org/10.1310/hpj5008-672
Rutledge, Matthew R, et al. "Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme." Hospital pharmacy vol. 50,8 (2015): 672-7. doi: https://doi.org/10.1310/hpj5008-672
Rutledge MR, Waddell JA, Solimando DA. Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme. Hosp Pharm. 2015 Sep;50(8):672-7. doi: 10.1310/hpj5008-672. Epub 2015 Sep 16. PMID: 26823616; PMCID: PMC4686471.
Copy Download .nbib Format: NLM
Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

Hospital pharmacy

Nguyen J, Solimando DA, Waddell JA.
PMID: 27354744
Hosp Pharm. 2016 Jun;51(6):442-9. doi: 10.1310/hpj5106-442.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Nguyen J, Solimando DA, Waddell JA. Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. Hosp Pharm. 2016;51(6):442-9doi: 10.1310/hpj5106-442.
Nguyen, J., Solimando, D. A., & Waddell, J. A. (2016). Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. Hospital pharmacy, 51(6), 442-9. https://doi.org/10.1310/hpj5106-442
Nguyen, Jamie, et al. "Carboplatin and Liposomal Doxorubicin for Ovarian Cancer." Hospital pharmacy vol. 51,6 (2016): 442-9. doi: https://doi.org/10.1310/hpj5106-442
Nguyen J, Solimando DA, Waddell JA. Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. Hosp Pharm. 2016 Jun;51(6):442-9. doi: 10.1310/hpj5106-442. PMID: 27354744; PMCID: PMC4911983.
Copy Download .nbib Format: NLM
Paclitaxel, Carboplatin, and trastuzumab.

Hospital pharmacy

Lee J, Solimando DA, Waddell JA.
PMID: 25477563
Hosp Pharm. 2014 Nov;49(10):913-9. doi: 10.1310/hpj4910-913.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Lee J, Solimando DA, Waddell JA. Paclitaxel, Carboplatin, and trastuzumab. Hosp Pharm. 2014;49(10):913-9doi: 10.1310/hpj4910-913.
Lee, J., Solimando, D. A., & Waddell, J. A. (2014). Paclitaxel, Carboplatin, and trastuzumab. Hospital pharmacy, 49(10), 913-9. https://doi.org/10.1310/hpj4910-913
Lee, Jennifer, et al. "Paclitaxel, Carboplatin, and trastuzumab." Hospital pharmacy vol. 49,10 (2014): 913-9. doi: https://doi.org/10.1310/hpj4910-913
Lee J, Solimando DA, Waddell JA. Paclitaxel, Carboplatin, and trastuzumab. Hosp Pharm. 2014 Nov;49(10):913-9. doi: 10.1310/hpj4910-913. PMID: 25477563; PMCID: PMC4252214.
Copy Download .nbib Format: NLM
Drug monographs: dabrafenib and trametinib.

Hospital pharmacy

Waddell JA, Solimando DA.
PMID: 24421433
Hosp Pharm. 2013 Nov;48(10):818-21. doi: 10.1310/hpj4810-818.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Waddell JA, Solimando DA. Drug monographs: dabrafenib and trametinib. Hosp Pharm. 2013;48(10):818-21doi: 10.1310/hpj4810-818.
Waddell, J. A., & Solimando, D. A. (2013). Drug monographs: dabrafenib and trametinib. Hospital pharmacy, 48(10), 818-21. https://doi.org/10.1310/hpj4810-818
Waddell, J Aubrey, and Solimando, Dominic A. "Drug monographs: dabrafenib and trametinib." Hospital pharmacy vol. 48,10 (2013): 818-21. doi: https://doi.org/10.1310/hpj4810-818
Waddell JA, Solimando DA. Drug monographs: dabrafenib and trametinib. Hosp Pharm. 2013 Nov;48(10):818-21. doi: 10.1310/hpj4810-818. PMID: 24421433; PMCID: PMC3859275.
Copy Download .nbib Format: NLM
Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome.

Hospital pharmacy

Lee JN, Solimando DA, Waddell JA.
PMID: 24421416
Hosp Pharm. 2013 Jan;48(1):14-22. doi: 10.1310/hpj4801-14.test.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Lee JN, Solimando DA, Waddell JA. Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome. Hosp Pharm. 2013;48(1):14-22doi: 10.1310/hpj4801-14.test.
Lee, J. N., Solimando, D. A., & Waddell, J. A. (2013). Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome. Hospital pharmacy, 48(1), 14-22. https://doi.org/10.1310/hpj4801-14.test
Lee, Jessica N, et al. "Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome." Hospital pharmacy vol. 48,1 (2013): 14-22. doi: https://doi.org/10.1310/hpj4801-14.test
Lee JN, Solimando DA, Waddell JA. Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome. Hosp Pharm. 2013 Jan;48(1):14-22. doi: 10.1310/hpj4801-14.test. PMID: 24421416; PMCID: PMC3839431.
Copy Download .nbib Format: NLM
Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer.

Hospital pharmacy

Rutledge MR, Waddell JA, Solimando DA.
PMID: 24421475
Hosp Pharm. 2013 Apr;48(4):274-9. doi: 10.1310/hpj4804-274.test.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Rutledge MR, Waddell JA, Solimando DA. Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer. Hosp Pharm. 2013;48(4):274-9doi: 10.1310/hpj4804-274.test.
Rutledge, M. R., Waddell, J. A., & Solimando, D. A. (2013). Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer. Hospital pharmacy, 48(4), 274-9. https://doi.org/10.1310/hpj4804-274.test
Rutledge, Matthew R, et al. "Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer." Hospital pharmacy vol. 48,4 (2013): 274-9. doi: https://doi.org/10.1310/hpj4804-274.test
Rutledge MR, Waddell JA, Solimando DA. Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer. Hosp Pharm. 2013 Apr;48(4):274-9. doi: 10.1310/hpj4804-274.test. PMID: 24421475; PMCID: PMC3839449.
Copy Download .nbib Format: NLM
Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer.

Hospital pharmacy

Garrett MJ, Waddell JA, Solimando DA.
PMID: 28804149
Hosp Pharm. 2017 May;52(5):341-347. doi: 10.1177/0018578717715353. Epub 2017 May 01.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Garrett MJ, Waddell JA, Solimando DA. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017;52(5):341-347doi: 10.1177/0018578717715353.
Garrett, M. J., Waddell, J. A., & Solimando, D. A. (2017). Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hospital pharmacy, 52(5), 341-347. https://doi.org/10.1177/0018578717715353
Garrett, Meghan J, et al. "Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer." Hospital pharmacy vol. 52,5 (2017): 341-347. doi: https://doi.org/10.1177/0018578717715353
Garrett MJ, Waddell JA, Solimando DA. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347. doi: 10.1177/0018578717715353. Epub 2017 May 01. PMID: 28804149; PMCID: PMC5551630.
Copy Download .nbib Format: NLM
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL).

Hospital pharmacy

Damery E, Solimando DA, Waddell JA.
PMID: 27698500
Hosp Pharm. 2016 Sep;51(8):628-632. doi: 10.1310/hpj5108-628.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Damery E, Solimando DA, Waddell JA. Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hosp Pharm. 2016;51(8):628-632doi: 10.1310/hpj5108-628.
Damery, E., Solimando, D. A., & Waddell, J. A. (2016). Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hospital pharmacy, 51(8), 628-632. https://doi.org/10.1310/hpj5108-628
Damery, Erin, et al. "Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL)." Hospital pharmacy vol. 51,8 (2016): 628-632. doi: https://doi.org/10.1310/hpj5108-628
Damery E, Solimando DA, Waddell JA. Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hosp Pharm. 2016 Sep;51(8):628-632. doi: 10.1310/hpj5108-628. PMID: 27698500; PMCID: PMC5030872.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 134 entries